Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05277051 · ClinicalTrials.gov registry record · Phase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

A Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
152
Enrollment target
20
Study locations

NCT05277051 is a Phase 1 study of Neoplasms that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 152 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05277051, a Phase 1 study of Neoplasms, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.

Conditions Studied

Neoplasms

Interventions

  • DRUG Dostarlimab
  • DRUG GSK5764227
  • DRUG Remzistotug
  • DRUG Belrestotug
  • DRUG Nelistotug

Study Locations (20)

Other

  • GSK Investigational Site - Chengdu
  • GSK Investigational Site - Jinan
  • GSK Investigational Site - Shanghai
  • GSK Investigational Site - Wuhan
  • GSK Investigational Site - Dijon
  • GSK Investigational Site - Lille
  • GSK Investigational Site - Chiba
  • GSK Investigational Site - Tokyo
  • GSK Investigational Site - Seoul
  • GSK Investigational Site - Seoul

Texas

  • GSK Investigational Site - Dallas
  • GSK Investigational Site - San Antonio

Ontario

  • GSK Investigational Site - Ottawa
  • GSK Investigational Site - Toronto

California

  • GSK Investigational Site - San Francisco

North Carolina

  • GSK Investigational Site - Charlotte

Oklahoma

  • GSK Investigational Site - Oklahoma City

Pennsylvania

  • GSK Investigational Site - Philadelphia

Utah

  • GSK Investigational Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2022-03-22
Est. Completion 2027-08-31
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05277051

The ClinicalTrials.gov registry entry for NCT05277051 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Dostarlimab is the first listed.

NCT05277051 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Texas, Ontario.

Frequently Asked Questions

What is clinical trial NCT05277051 about?

NCT05277051 is a clinical study titled "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors". This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been e...

What is the current status of trial NCT05277051?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2022-03-22. Estimated completion is 2027-08-31.

What conditions does trial NCT05277051 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT05277051?

The interventions under investigation include: Dostarlimab (DRUG), GSK5764227 (DRUG), Remzistotug (DRUG), Belrestotug (DRUG), Nelistotug (DRUG).

Who is sponsoring clinical trial NCT05277051?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05277051 being conducted?

This trial has 20 study locations across California, North Carolina, Oklahoma, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.